Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS

The third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), osimertinib, aumolertinib, and furmonertinib represent a new treatment option for patients with EGFR p.Thr790 Met (T790 M)-mutated non-small cell lung cancer (NSCLC). Currently, there are no studies reporti...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ying Li, Lu Meng, Yinling Ma, Yajing Li, Xiaoqing Xing, Caihui Guo, Zhanjun Dong
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-07-01
Edice:	Molecules
Témata:	UPLC-MS/MS osimertinib aumolertinib furmonertinib therapeutic drug monitoring
On-line přístup:	https://www.mdpi.com/1420-3049/27/14/4474
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!